|Day Low/High||81.67 / 82.58|
|52 Wk Low/High||60.32 / 82.86|
ABT has been in a strong and durable uptrend and that is likely to continue.
Don't worry about missing anything, we haven't solved the bond conundrum and the evidence says we get to 3% with selloffs on the way.
John Flannery sees progress being made on GE's initiatives, but that is what I expected him to say.
It's hard to understand the magnitude of the change.
Treasury secretary says it's baked into the market, but is anyone really counting on it?
Jim Cramer weighs in on the trending news of the day from the floor of the New York Stock Exchange.
Jim Cramer explains why his Action Alerts Plus charitable portfolio is hanging on to Abbott Laboratories.
Stay long, and consider raising sell-stop protection to a close below $50.
Working Mother and the National Association of Female Executives surveyed companies and found the best ones that do right by women. Find out who you should be working for.
EY's Kerrie MacPherson Wants To Pave the Way for future female entrepreneurs.
A rotation that started as the minor chord of the rotational symphony and is now the major one.
Barring a close below $46, we are likely to see ABT remain firm and work higher.
Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.
It's a wonder to me how split this market really is.
Medtronic, Abbott Labs and Becton Dickinson appear to be offering buying opportunities.
Earnings take center stage again with a disappointment from IBM and a better-than-expected performance from Morgan Stanley dividing markets.
Their overseas business has been carrying them.
We know that we are in the era when index managers are ascendant.
There are nearly too many surging sectors to count.